Letter by Kleipool et al Regarding Article, “Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
The meta-analysis on primary prevention with statins in the elderly by Ridker and colleagues1 concludes that data from existing trials support the use of statins in primary prevention among those ≥70 years of age and supposedly also among those ≥80 years. As the authors state, uncertainties remain with regard to possible long-term side effects, effects on quality of life, and potentially modest effect on longevity. We would like to emphasize these concerns because data on these issues are scarce and based on studies …